EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat

Kathleen R Ruddiman, Catherine E Price, Alexander K Bonnecaze

AACE Clinical Case Reports · 2025-01 · 11 (1) · 53-57

DOI: 10.1016/j.aace.2024.10.005 ↗

Kurz gefasst

Fallbericht in der Zeitschrift AACE Clinical Case Reports, 2025-01. Verfasst von Kathleen R Ruddiman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC). Case Report: A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal mass and hypercortisolism. Right adrenalectomy was pursued with pathology consistent with diagnosis of ACC. Three months after surgery, hypercortisolemia recurred and bony metastatic disease was detected soon after. The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia. The patient's urinary free cortisol became severely elevated, and osilodrostat was subsequently initiated for steroidogenesis inhibition. As dosage was increased, the patient presented with fatigue and hypotension and was diagnosed with adrenal insufficiency. This was managed with hydrocortisone in a block-and-replace dosing strategy.

Discussion

ACC can cause severe hypercortisolism, which is associated with significant morbidity and mortality. Osilodrostat was an effective off-label option for steroidogenesis inhibition in our patient who developed severe hypercortisolism and did not tolerate first-line therapy. Our patient also experienced iatrogenic adrenal insufficiency during treatment with osilodrostat, which was successfully managed using a block-and-replace strategy. There are limited cases currently available that document use of osilodrostat under the above circumstances.

Conclusion

Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency.

Schlagwörter

Stichwörter der Autor:innen

Cushing syndromeadrenocortical carcinomablock-and-replacehypercortisolismosilodrostat

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina.
  • Department of Endocrinology, Pinehurst Medical Clinic, Pinehurst, North Carolina.

Zitieren

APA

Ruddiman, K. R., Price, C. E., & Bonnecaze, A. K. (2025). A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat. AACE Clinical Case Reports, 11(1), 53-57. https://doi.org/10.1016/j.aace.2024.10.005

Vancouver

Ruddiman KR, Price CE, Bonnecaze AK. A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat. AACE Clinical Case Reports. 2025;11(1):53-57. doi:10.1016/j.aace.2024.10.005

BibTeX
@article{Ruddiman2025,
  author = {Ruddiman, Kathleen R and Price, Catherine E and Bonnecaze, Alexander K},
  title = {A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat},
  journal = {AACE Clinical Case Reports},
  year = {2025},
  volume = {11},
  number = {1},
  pages = {53--57},
  doi = {10.1016/j.aace.2024.10.005}
}
Kostenlos starten →